• Eisai, BMS Enter Global Anticancer ADC Alliance contractpharma
    June 21, 2021
    ​Eisai Co., Ltd. and Bristol-Myers Squibb Co. entered an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
PharmaSources Customer Service